These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18443809)

  • 1. [Methotrexate: advantages of subcutaneous administration].
    Krüger K
    Z Rheumatol; 2008 Jul; 67(4):332-3. PubMed ID: 18443809
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials.
    Parker CT; Mewshaw E; Dennis GJ
    J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis.
    Hameed B; Jones H
    Int J Rheum Dis; 2010 Oct; 13(4):e83-4. PubMed ID: 21199461
    [No Abstract]   [Full Text] [Related]  

  • 5. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
    Raghu P; Grover PS; Kumar A
    Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
    Alsaeedi S; Keystone EC
    Nat Rev Rheumatol; 2014 Oct; 10(10):578-9. PubMed ID: 25090946
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral methotrexate: the hazard of different tablet strengths.
    Schott JM; Rigby SP; McNally JD; Keat A; Higgens CS
    Rheumatology (Oxford); 1999 Apr; 38(4):382. PubMed ID: 10378725
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term combination therapy of chronic polyarthritis: methotrexate and parenteral gold].
    Krause D
    Z Rheumatol; 1998 Feb; 57(1):37-40. PubMed ID: 9566106
    [No Abstract]   [Full Text] [Related]  

  • 10. Parenteral methotrexate for the treatment of rheumatoid arthritis.
    Yazici Y; Bata Y
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methotrexate for therapy of rheumatoid arthritis].
    Suzuki Y; Wakabayashi T; Jackson K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():498-502. PubMed ID: 15799406
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of chronic polyarthritis with methotrexate 1994--a review].
    Rau R
    Z Rheumatol; 1994; 53(4):199-229. PubMed ID: 7975933
    [No Abstract]   [Full Text] [Related]  

  • 13. Superficial Tissue Necrosis Related to Methotrexate Injection in a Patient With Rheumatoid Arthritis.
    Estrada Alarcon PV; García-Díaz S; Oña M; Corominas H
    J Clin Rheumatol; 2015 Oct; 21(7):370. PubMed ID: 26398466
    [No Abstract]   [Full Text] [Related]  

  • 14. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.
    Bakker MF; Jacobs JW; Welsing PM; van der Werf JH; Linn-Rasker SP; van der Veen MJ; Lafeber FP; Bijlsma JW;
    Ann Rheum Dis; 2010 Oct; 69(10):1849-52. PubMed ID: 20511610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit and risk of methotrexate treatment in rheumatoid arthritis.
    Rau R; Herborn G
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S83-94. PubMed ID: 15552520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of rheumatoid arthritis with etanercept].
    Lamprecht P; Nitschmann S
    Internist (Berl); 2009 May; 50(5):633-4. PubMed ID: 19350212
    [No Abstract]   [Full Text] [Related]  

  • 17. [The initial results of the Metex Study].
    Braun J
    Krankenpfl J; 2005; 43(7-10):246-7. PubMed ID: 16515316
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA.
    Rau R
    J Rheumatol; 2005 Jul; 32(7):1412; author reply 1412-3. PubMed ID: 15996092
    [No Abstract]   [Full Text] [Related]  

  • 19. What dose of folic acid to use with methotrexate in rheumatoid arthritis?
    Bramley D
    Drug Ther Bull; 2021 Jul; 59(7):103-106. PubMed ID: 34162667
    [No Abstract]   [Full Text] [Related]  

  • 20. [Subcutaneous self-administration of methotrexate in rheumatoid arthritis].
    Huisman AM; Schouten JP; van Paassen HC; Wouters JM; Jacobs JW
    Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1564-5. PubMed ID: 8765767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.